San Diego, CA -- (SBWIRE) -- 04/08/2015 -- An investigation on behalf of investors of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) shares over potential securities laws violations by Can Fite Biopharma Ltd and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) concerning whether a series of statements by Can Fite Biopharma Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 30, 2015, Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) (TASE:CFBI) announced that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint. On this news, the price of Can-Fite's shares declined by over 60%

Those who purchased shares of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com